10-01 :: January 2010
nanotimes
27
Companies
Facts
P
lastic Logic unveiled QUE™ (pronounced „Q“), development at pSivida, which can help to get drugs
the world’s first proReader (see page 15). More directly to the area of the eye where they can be
than an eReader, QUE™ is designed specifically to most effective in treating the underlying disease. As
provide a premium reading experience and access part of this presentation, Dr. Ashton also presented
to content anywhere anytime, while simplifying the recent top-line results of the Phase 3 FAME™ trials of
multi-faceted lifestyle of business professionals – and Iluvien
®
in patients with diabetic macular edema that
to literally lighten their workload. With its sleek 8.5 x were reported last month by pSivida and its licensee,
11 inch form factor, crisp large touchscreen display, Alimera Sciences.
intuitive user interface and powerful tools, QUE™

http://www.psivida.com
stands out in the crowd.
http://www.plasticlogic.com
D
TE Energy Ventures has invested $3 million in
QD Vision, Inc., developer of Quantum
P
olymer Group, Inc. (OTCBB: POLGA; POLGB; Light™ nanotechnology-based products for solid
(PGI)) has signed a definitive agreement to ac- state lighting and displays. The funding will support
quire the Barcelona, Spain-based Tesalca-Texnovo QD Vision’s market expansion of quantum dot-based
nonwovens businesses from Grupo Corinpa, S.L. in nanomaterials that enable major efficiency gains in
a two-phase process. PGI is a leading global engi- high-quality solid-state lighting and flat panel dis-
neered materials company, focused primarily on the plays. “This technology promises to set a new stan-
production of nonwovens for the hygiene, wipes, dard for these multi-billion dollar global industries.”
medical, and industrial markets. The investment follows a $10 million initial close of

http://www.pginw.com/en/ funding announced last month by the company.
p
Sivida Corp. (NASDAQ:PSDV; ASX:PVA), “DTE Energy’s investment in QD Vision is a signifi-
a leader in the development of tiny, sustained- cant endorsement of our Quantum Light™ product
release drug delivery technologies, with two of the platform, which will improve the quality of solid state
only three ophthalmic sustained-release delivery lighting and displays while dramatically reducing po-
products approved by the FDA for treatment of back wer consumption and costs,” said Dan Button, CEO
of the eye diseases, announced that its Chief Execu- of QD Vision. “DTE Energy is actively participating
tive Officer, Dr. Paul Ashton, discussed ocular drug in developing clean-energy solutions with its invest-
delivery in diabetic retinopathy during a presentation ments in some of the world’s most exciting startups
at the 6th Annual Diabetes Conference in London, in renewable energy, energy efficiency and energy
on Friday, January 22. In his presentation Dr. Ashton storage solutions.”
described the barriers to clinically effective therapies Since 2004 QD Vision has raised a total of $33 milli-
in diabetic retinopathy and the difficulty of getting on in venture capital financing.
drugs to the back of the eye, where most diabetic

http://www.qdvision.com
eye disease manifests itself. He discussed emerging
drug delivery technologies, including those under